TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21332800

Group type: EXPERIMENTAL
Intervention: Cow's milk-based human milk fortifier (HMF) added to mother's milk while breastfeeding
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cow's milk-based preterm formula
Number of subjects: 324

Group type: COMPARATOR
Intervention: Exclusively mother's milk
Number of subjects: 324

Group type: COMPARATOR
Intervention: Cow's milk-based human milk fortifier (HMF) or preterm formula
Number of subjects: 324
Study: 19757993

Group type: EXPERIMENTAL
Intervention: Switch to raltegravir
Number of subjects: 170

Group type: COMPARATOR
Intervention: Maintenance of enfuvirtide
Number of subjects: 170
Study: 18534481

Group type: EXPERIMENTAL
Intervention: Outpatient physiotherapy for 6 weeks (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No outpatient physiotherapy (group B)
Number of subjects: 150
Study: 14998954

Group type: EXPERIMENTAL
Intervention: Modified laser-assisted ICSI
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Conventional ICSI (control group)
Number of subjects: 1016
Study: 11678828

Group type: EXPERIMENTAL
Intervention: Pegvisomant (80 mg as a single subcutaneous injection)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fasting (3 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of fasting and pegvisomant
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9252944

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 67
Study: 8517932

Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg IV in the first 6 hours of life, then 2.5 mg/kg IV every 12 hours for the next five days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not treated with phenobarbital
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenobarbital treatment
Number of subjects: 60
Study: 3646618

Group type: EXPERIMENTAL
Intervention: Water-fed group (up to 30 ml of sterile water at each feeding at 1, 2, and 3 HOL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formula-fed group (fed formula at the same times and in the same amounts as the water-fed group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (routine hospital feeding of up to 30 ml of sterile water at 4 HOL and up to 30 ml of formula at 8 HOL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water-fed group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formula-fed group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 11302970

Group type: EXPERIMENTAL
Intervention: Intralipid 2 kcal/min (high fat)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intralipid 0.5 kcal/min (low fat)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study: 31535609

Group type: EXPERIMENTAL
Intervention: Coping interventions
Number of subjects: 240

Group type: COMPARATOR
Intervention: High-conflict trajectories
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 240
Study: 30332542

Group type: EXPERIMENTAL
Intervention: Intervention group (inputs and training for poultry farming and home gardening, and nutrition and health education)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 26374114

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Morphine (0.5% bupivacaine 100 mg + morphine 2 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Bupivacaine + Tenoxicam (0.5% bupivacaine 100 mg + tenoxicam 20 mg)
Number of subjects: 240
Study: 25073008

Group type: EXPERIMENTAL
Intervention: Sacral magnetic stimulation (SMS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study: 22469284

Group type: EXPERIMENTAL
Intervention: Low intensity cognitive behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 20645395

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent clamping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions (including antioxidants, anti-inflammatory drugs, vasodilators, pharmacological preconditioning, glucose infusion)
Number of subjects: 0
Study: 17657865

Group type: EXPERIMENTAL
Intervention: Electronic version of the Chinese SF-36
Number of subjects: 150

Group type: COMPARATOR
Intervention: Paper version of the Chinese SF-36
Number of subjects: 150
Study: 15701468

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Pharmacological therapy (loop diuretics, ACE inhibitors/ARBs, beta-blockers, spironolactone)
Number of subjects: 813
Study: 12083314

Group type: EXPERIMENTAL
Intervention: Phytostanol treatment (3 g/d in 3 servings)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phytostanol treatment
Number of subjects: 12
Study: 10087722

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 30 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 7488893

Group type: EXPERIMENTAL
Intervention: Two view mammography
Number of subjects: 40163

Group type: COMPARATOR
Intervention: One view mammography
Number of subjects: 40163
Study: 1971586

Group type: EXPERIMENTAL
Intervention: Xamoterol (0.2 mg kg‐1 by infusion over 5 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7408527

Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg, 3 times a day for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin 1000 mg, 3 times a day for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo during 2-day intervals
Number of subjects: 20
Study: 31969363

Group type: EXPERIMENTAL
Intervention: Self-reported computerised history taking (CHT) using a tablet.
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard history taking.
Number of subjects: 2000
Study: 31039674

Group type: EXPERIMENTAL
Intervention: Lower extremity VMRT training for 4 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Upper extremity VMRT training for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 37
Study: 28489495

Group type: EXPERIMENTAL
Intervention: Monitoring suicide ideation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suicide protocol
Number of subjects: 0
Study: 26500169

Group type: EXPERIMENTAL
Intervention: SMART-CPT (hybrid treatment integrating CogSMART into cognitive processing therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CPT (Cognitive Processing Therapy)
Number of subjects: 0
Study: 24186866

Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Metformin and Sitagliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 22317067

Group type: EXPERIMENTAL
Intervention: Intervention subjects (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 19205719

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin four times per day in both eyes for at least 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin for a minimum of 1 day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eyelid scrub in addition to topical levofloxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 60
Study: 17602062

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, 3.0 microg/kg every 2 weeks (Q2W)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 285
Study: 15225585

Group type: EXPERIMENTAL
Intervention: Vitamin C (500mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin E (400IU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin C and/or E
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin C and E (combined)
Number of subjects: 12
Study: 11687463

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copolymer 1; Copaxone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9313670

Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 45
Study: 8184644

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 2967310

Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acitretin 75 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acitretin 10 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acitretin 25 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31743233

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31157360

Group type: EXPERIMENTAL
Intervention: Active amyloid-β42 immunization (AN1792)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 27748563

Group type: EXPERIMENTAL
Intervention: Implicit priming aimed at increasing positive expectations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 36
Study: 26515802

Group type: EXPERIMENTAL
Intervention: Group A (<40 years)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Group B (≥40 years)
Number of subjects: 53
Study: 24124176

Group type: EXPERIMENTAL
Intervention: Printed erotic material (X-rated, soft-core magazines) provided during semen collection
Number of subjects: 1520

Group type: COMPARATOR
Intervention: No printed erotic material provided during semen collection
Number of subjects: 1520
Study: 22056247

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily, with possible increases to 7 mg and 10 mg)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 723

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 723
Study: 19405825

Group type: EXPERIMENTAL
Intervention: Non-submerged hollow cylindrical and solid-screw implants with titanium plasma-sprayed surface
Number of subjects: 192
Study: 16461042

Group type: EXPERIMENTAL
Intervention: Manual pressure hemostasis after transfemoral coronary angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuing warfarin > or =48 hours before the procedure (INR <2.0)
Number of subjects: 0
Study: 15759600

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement (3.9 g total carbohydrates, 0.5 g glucose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10735262

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-to-head comparisons
Number of subjects: 0
Study: 8803518

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms per day in week 1, 1600 micrograms per day in week 2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluticasone 750 micrograms per day in week 1, 1500 micrograms per day in week 2
Number of subjects: 9
Study: 1611231

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 20
Study: 6373961

Group type: EXPERIMENTAL
Intervention: B subunit (low dose, 1.0 mg)
Number of subjects: 1922

Group type: EXPERIMENTAL
Intervention: B subunit (high dose, 5.0 mg)
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1922
Study: 31685853

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) paired with upper-limb rehabilitation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (upper-limb rehabilitation without VNS)
Number of subjects: 35
Study: 28742932

Group type: EXPERIMENTAL
Intervention: Integrated 12-Step facilitation (iTSF) treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Motivational enhancement therapy/cognitive-behavioral therapy (MET/CBT)
Number of subjects: 59
Study: 26033801

Group type: EXPERIMENTAL
Intervention: MAP plus IFN‐α‐2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration)
Number of subjects: 716

Group type: COMPARATOR
Intervention: MAP alone
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: MAP plus IFN‐α‐2b
Number of subjects: 716
Study: 22855233

Group type: EXPERIMENTAL
Intervention: Bilateral robotic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral robotic training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21479749

Group type: EXPERIMENTAL
Intervention: Etodolac controlled porosity osmotic pump (CPOP) tablets (F4-34)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial immediate-release Napilac® capsules
Number of subjects: 0
Study: 19560810

Group type: EXPERIMENTAL
Intervention: 50 mg golimumab
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: 100 mg golimumab
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 17710801

Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20), Wangu (GB 12), and Tianzhu (BL 10) plus oral leech capsules and centipede capsules
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous drip of compound Danshen injection and oral aspirin
Number of subjects: 30
Study: 15100686

Group type: COMPARATOR
Intervention: Aspirin (dose not specified)
Number of subjects: 74
Study: 11803060

Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE (5log(10)PFU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE (4log(10)PFU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: YF-VAX (5log(10)PFU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE
Number of subjects: 12

Group type: COMPARATOR
Intervention: ChimeriVax-JE and YF 17D
Number of subjects: 12
Study: 10432262

Group type: EXPERIMENTAL
Intervention: 6-month exercise protocol (daily performance of five shoulder exercises: two for stretching anterior shoulder musculature and three for strengthening posterior shoulder musculature)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study: 7580546

Group type: EXPERIMENTAL
Intervention: Chemotherapy with radical radiotherapy
Number of subjects: 9387

Group type: EXPERIMENTAL
Intervention: Chemotherapy with supportive care
Number of subjects: 9387

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 9387

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy plus chemotherapy
Number of subjects: 9387

Group type: EXPERIMENTAL
Intervention: Supportive care plus chemotherapy
Number of subjects: 9387
Study: 2024984

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05%
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.01%
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.001%
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05%, 0.01%, 0.001%
Number of subjects: 533

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 533
Study: 6941670

Group type: EXPERIMENTAL
Intervention: Letter identification task (L) in HT group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Letter identification task (L) in NT group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mental arithmetic (MA) in HT group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mental arithmetic (MA) in NT group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall results in HT group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Overall results in NT group
Number of subjects: 28
Study: 6322961

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (weekly schedule: 1 gram per square meter BSA every 8 hours for two doses per week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (daily schedule: 250 mg per day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (weekly schedule)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 44
Study: 31928507

Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration with sclerotherapy (PAS) using 95% ethanol, n = 40
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laparoscopic marsupialization (LM) under general anesthesia, n = 40
Number of subjects: 80
Study: 28771784

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine treatment intensifications
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Asparaginase de-escalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard or experimental treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physician's expertise
Number of subjects: 16
Study: 26811171

Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall intervention satisfaction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Communication among multidisciplinary team
Number of subjects: 150
Study: 24062200

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control patch with low-dose capsaicin 0.075% cream
Number of subjects: 11
Study: 22749368

Group type: COMPARATOR
Intervention: HDWL endoscopy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: HDWL + pCLE
Number of subjects: 119
Study: 20416218

Group type: EXPERIMENTAL
Intervention: Compound glycyrrhizin treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 52
Study: 18713215

Group type: EXPERIMENTAL
Intervention: Inpatient interdisciplinary rehabilitation program
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care (discharge back to the nursing home soon after surgery)
Number of subjects: 11
Study: 15625362

Group type: EXPERIMENTAL
Intervention: TPZ/CIS (Tirapazamine and Cisplatin)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemoboost (Cisplatin and Fluorouracil)
Number of subjects: 122
Study: 12536162

Group type: EXPERIMENTAL
Intervention: Prism exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prism exposure (baseline)
Number of subjects: 0
Study: 10655967

Group type: EXPERIMENTAL
Intervention: Broccoli meal (300 g/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Green peas meal (300 g/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Spinach meal (300 g/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplemented meal (33.3 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Disruption of spinach matrix
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All vegetable meals (broccoli, green peas, spinach)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Broccoli and green peas (per mg carotenoid consumed)
Number of subjects: 69
Study: 8753922

Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 60

Group type: COMPARATOR
Intervention: McCoy blade
Number of subjects: 60
Study: 1909469

Group type: EXPERIMENTAL
Intervention: Glucantime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interferon-gamma
Number of subjects: 40
Study: 6874179

Group type: EXPERIMENTAL
Intervention: Static handgrip at 30% of maximal voluntary contraction for 3 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Leg extension at 30% of maximal voluntary contraction for 3 min
Number of subjects: 12
Study: 30688872

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study: 29863280

Group type: EXPERIMENTAL
Intervention: DWP14012 (10-320 mg single dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DWP14012 (20-160 mg once daily for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Esomeprazole (active comparator)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26822418

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with physical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo current combined with physical therapy
Number of subjects: 40
Study: 24440678

Group type: EXPERIMENTAL
Intervention: 8 F Perclose ProGlide (n = 50)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 10 F Prostar XL (n = 51)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Open femoral exposure (n = 50)
Number of subjects: 151
Study: 22297243

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 20638815

Group type: EXPERIMENTAL
Intervention: Warm, empathic communication with positive expectations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold, formal communication with positive expectations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warm, empathic communication with uncertain expectations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold, formal communication with uncertain expectations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warm, empathic communication
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GP suggestions about outcomes
Number of subjects: 30
Study: 18372696

Group type: EXPERIMENTAL
Intervention: Exercise countermeasure (LBNP-treadmill plus flywheel, EX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-exercise (No-EX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-EX
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 24